Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVRA vs TYLOX-325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.
Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.
Onchocerciasis (river blindness),Strongyloidiasis (threadworm infection),Scabies (off-label, FDA-approved for scabies in certain contexts; also used off-label for head lice, pediculosis, and various parasitic infections)
Management of moderate to severe pain requiring an opioid analgesic,Severe pain uncontrolled by non-opioid analgesics
Intravenous 500 mg every 6 hours.
1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in elderly patients.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Oxycodone: 3-5 hours (extended-release preparation); terminal half-life 4.5-5.5 hours. Clinical context: repeated dosing may lead to accumulation; half-life prolongation in elderly, renal or hepatic disease.
Primarily metabolized by CYP3A4 in the liver; also a substrate for P-glycoprotein (P-gp) transporter.
Acetaminophen is primarily metabolized via conjugation (glucuronidation and sulfation) and via CYP2E1 (minor pathway forming toxic NAPQI). Oxycodone is metabolized via CYP3A4 (to noroxycodone) and CYP2D6 (to oxymorphone).
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; fecal/biliary excretion is the primary route (60-70% as metabolites, primarily unchanged drug via bile).
Renal: acetaminophen metabolites (60-70% as glucuronide conjugate, 20-30% as sulfate conjugate, 5-10% as cysteine conjugate, 5% unchanged). Oxycodone: renal (primarily metabolites, <10% unchanged); biliary/fecal: minor (oxycodone metabolites).
Approximately 85-90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin). Oxycodone: 45% (primarily albumin).
0.6-0.8 L/kg, indicating distribution into total body water with some extravascular binding; increased in heart failure or severe hepatic disease.
Acetaminophen: 0.9-1.0 L/kg; extensive distribution. Oxycodone: 2.6-3.6 L/kg; high tissue penetration including CNS.
Oral: 70-80% (extensive first-pass metabolism reduces from 90% absorbed); Intravenous: 100%.
Acetaminophen: oral 85-90%. Oxycodone: oral 60-87% (variable first-pass metabolism).
GFR >60 m L/min: 500 mg q6h; GFR 30-60: 250 mg q6h; GFR 15-30: 250 mg q12h; GFR <15: 250 mg q24h.
e GFR 30-60 m L/min: administer at reduced frequency (e.g., every 8-12 hours); e GFR <30 m L/min: avoid use or use with extreme caution (reduce dose by 50% and monitor); hemodialysis: not recommended due to acetaminophen accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg q6h; Child-Pugh C: 250 mg q12h.
Child-Pugh A (mild): no adjustment necessary; Child-Pugh B (moderate): reduce oxycodone dose by 50% and limit acetaminophen to ≤2000 mg/day; Child-Pugh C (severe): contraindicated.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Not approved for children <18 years; weight-based dosing: oxycodone 0.05-0.15 mg/kg/dose (max 5 mg) and acetaminophen 10-15 mg/kg/dose (max 650 mg) orally every 4-6 hours as needed; total daily acetaminophen ≤75 mg/kg/day.
Same as adult; monitor renal function and adjust per GFR.
Initiate at lowest dose (e.g., 1 capsule every 6 hours); titrate cautiously; avoid in patients with renal impairment or hepatic dysfunction; monitor for opioid-induced constipation, respiratory depression, and acetaminophen hepatotoxicity; consider alternative non-opioid analgesics if feasible.
None.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; interaction with alcohol.
Potential for severe adverse reactions (Mazzotti reaction) in onchocerciasis patients; neurotoxicity (especially in elderly or patients with high drug levels); avoid use in patients with impaired hepatic function; caution with concomitant use of CNS depressants; not recommended in pregnancy (Category C).
Respiratory depression, opioid-induced hyperalgesia, adrenal insufficiency, severe hypotension, seizures, serotonin syndrome, hepatotoxicity, risk of overdose with acetaminophen, risks of use in patients with head injury or increased intracranial pressure.
Hypersensitivity to ivermectin or any component of the formulation; not for use in pediatric patients weighing less than 15 kg for scabies treatment (due to risk of neurotoxicity).
Hypersensitivity to acetaminophen or oxycodone, significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, paralytic ileus.
No food interactions with IVRA technique; however, lidocaine administration may be affected by grapefruit juice (inhibits metabolism) — avoid grapefruit juice before procedure.
Avoid alcohol. High-fat meals may delay absorption of oxycodone but do not significantly alter overall exposure. No specific food restrictions beyond alcohol.
IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal nephrotoxicity, oligohydramnios, and premature ductus arteriosus closure.
Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome (NOWS). Third trimester: high doses near term may cause neonatal respiratory depression.
Excreted into breast milk in low amounts; M/P ratio 0.3. Avoid use due to potential adverse effects in nursing infants (renal impairment, bleeding).
Oxycodone is excreted in breast milk; M/P ratio approximately 3.4:1. American Academy of Pediatrics recommends cautious use; monitor infant for drowsiness, respiratory depression. Acetaminophen is compatible with breastfeeding. Overall, risk to infant is low with short-term maternal use.
No dose adjustment is recommended as IVRA is contraindicated. In case of inadvertent use in pregnancy, discontinue immediately.
Increased clearance and volume of distribution during pregnancy may require dose adjustment. Pharmacokinetic changes: oxycodone clearance increases up to 1.6-fold in third trimester; acetaminophen clearance unchanged. Clinical monitoring of pain and adverse effects recommended; dose may need upward titration.
IVRA (intravenous regional anesthesia) is not a drug but a technique. For Bier block using lidocaine, use 0.5% preservative-free lidocaine, 3 mg/kg for upper extremity. Avoid in patients with sickle cell disease or severe hypertension. Monitor for tourniquet pain after 30 minutes; deflate tourniquet gradually to prevent systemic toxicity.
Tylox-325 contains oxycodone and acetaminophen. Avoid in patients with known hypersensitivity to opioids or acetaminophen. The maximum daily acetaminophen dose is 4 g; monitor for hepatotoxicity. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Coadministration with CNS depressants (e.g., benzodiazepines) increases risk of respiratory depression. Constipation is common; prescribe stool softeners prophylactically. Discontinue gradually to avoid withdrawal.
You will receive local anesthetic injected into a vein in your arm after a tourniquet is applied.,The tourniquet will be kept inflated during the procedure to keep the medication in the arm.,You may feel a burning sensation when the medication is injected, which is normal.,Do not remove the tourniquet yourself; it will be deflated slowly by the doctor to prevent side effects.,Report any chest discomfort, ringing in ears, or metallic taste immediately.
Take exactly as prescribed; do not exceed 4 grams of acetaminophen per day from all sources.,Avoid alcohol while taking this medication.,May cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how this medication affects you.,Do not take with other medications containing acetaminophen without consulting your doctor.,Contact your doctor if you experience signs of liver damage (yellow skin/eyes, dark urine, abdominal pain) or respiratory depression (slow/shallow breathing).,Store securely out of reach of others; this medication can be habit-forming and may be a target for misuse.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVRA vs TYLOX-325, answered by our medical review team.
IVRA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.. TYLOX-325 is a Opioid analgesic combination that works by Acetaminophen and oxycodone combination. Acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Oxycodone is a mu-opioid receptor agonist, activating descending pain pathways and altering pain perception.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVRA and TYLOX-325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVRA is: Intravenous 500 mg every 6 hours.. The standard adult dose of TYLOX-325 is: 1-2 capsules (oxycodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum 12 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVRA and TYLOX-325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVRA is classified as Category C. IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal n. TYLOX-325 is classified as Category C. Pregnancy Category C. Oxycodone crosses placenta. First trimester: risk of neural tube defects not established; avoid unless benefit outweighs risk. Second/third trimester: chronic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.